- Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time.
- Combines PharmaCielo’s expertise in producing premium medicinal cannabis products, with CANNPRISMA’s conversion capabilities, to bring patients in Europe the highest quality high-THC flower product currently available in the market.
Toronto, Ontario and Rionegro, Colombia–(Newsfile Corp. – April 19, 2023) – PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (“PharmaCielo” or the “Company”), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced that it has partnered with CANNPRISMA – PHARMA, LDA (“CANNPRISMA”), a Portuguese Contract Manufacturing Organization (“CMO”), to supply high-quality EU-GMP1 certified medicinal cannabis flower to the European market. PharmaCielo will provide GACP2 flower to CANNPRISMA, which will convert the flower to EU-GMP standards and distribute it directly from Portugal to European customers. CANNPRISMA is a Portuguese medical cannabis company founded in 2018 that encompasses all aspects of the production process, from cultivation to distribution and research. The company’s main objective is to provide high-quality medicinal cannabis products that comply with GACP and GMP standards, and serve as a reference in the market, ultimately contributing to enhancing the quality of life for as many people as possible.
Bill Petron, CEO of PharmaCielo, said, “We are very pleased to announce this agreement to ship THC-dominant dried flower to the European market. Against a tough macro backdrop for all publicly traded cannabis companies, PharmaCielo has taken the right steps to ensure it is positioned to drive results and build value for shareholders as the sales team continues to deliver on its growing pipeline of opportunities.”
